Bismaleimide cross‐linked anthrax toxin forms functional octamers with high specificity in tumor targeting
Open Access
- 3 April 2019
- journal article
- research article
- Published by Wiley in Protein Science
- Vol. 28 (6) , 1059-1070
Abstract
In recent years, anthrax toxin has been reengineered to act as a highly specific antiangiogenic cancer therapeutic, shown to kill tumors in animal models. This has been achieved by modifying protective antigen (PA) so that its activation and toxicity require the presence of two proteases, matrix metalloproteinase (MMP) and urokinase plasminogen activator (uPA), which are upregulated in tumor microenvironments. These therapeutics consist of intercomplementing PA variants, which are individually nontoxic, but form functional toxins upon complementary oligomerization. Here, we have created a dual‐protease requiring PA targeting system which utilizes bismaleimide cross‐linked PA (CLPA) rather than the intercomplementing PA variants. Three different CLPA agents were tested and, as expected, found to exclusively form octamers. Two of the CLPA agents have in vitro toxicities equal to those of previous intercomplementing agents, while the third CLPA agent had compromised in vitro cleavage and was significantly less cytotoxic. We hypothesize this difference was due to steric hindrance caused by cross‐linking two PA monomers in close proximity to the PA cleavage site. Overall, this work advances the development and use of the PA and LF tumor‐targeting system as a practical cancer therapeutic, as it provides a way to reduce the drug components of the anthrax toxin drug delivery system from three to two, which may lower the cost and simplify testing in clinical trials.HIGHLIGHT: Previously, anthrax toxin has been reengineered to act as a highly specific antiangiogenic cancer therapeutic. Here, we present a version, which utilizes bismaleimide cross‐linked protective antigen (PA) rather than intercomplementing PA variants. This advances the development of anthrax toxin as a practical cancer therapeutic as it reduces the components of the drug delivery system to two, which may lower the cost and simplify testing in clinical trials.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases (ZIA AI000929‐15)
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Institute of Dental and Craniofacial Research
This publication has 51 references indexed in Scilit:
- Anthrax Edema Factor Toxicity Is Strongly Mediated by the N-end RulePLOS ONE, 2013
- Anthrax Lethal Factor Cleavage of Nlrp1 Is Required for Activation of the InflammasomePLOS Pathogens, 2012
- Efficient Targeting of Head and Neck Squamous Cell Carcinoma by Systemic Administration of a Dual uPA and MMP-Activated Engineered Anthrax ToxinPLOS ONE, 2011
- Inhibition of Tumor Angiogenesis by the Matrix Metalloproteinase–Activated Anthrax Lethal Toxin in an Orthotopic Model of Anaplastic Thyroid CarcinomaMolecular Cancer Therapeutics, 2010
- The Protective Antigen Component of Anthrax Toxin Forms Functional Octameric ComplexesJournal of Molecular Biology, 2009
- Matrix Metalloproteinase–Activated Anthrax Lethal Toxin Inhibits Endothelial Invasion and Neovasculature Formation during In vitro MorphogenesisMolecular Cancer Research, 2009
- Cytotoxicity of the matrix metalloproteinase–activated anthrax lethal toxin is dependent on gelatinase expression and B-RAF status in human melanoma cellsMolecular Cancer Therapeutics, 2008
- Matrix Metalloproteinase-activated Anthrax Lethal Toxin Demonstrates High Potency in Targeting Tumor VasculatureJournal of Biological Chemistry, 2008
- Analytical Ultracentrifugation: Sedimentation Velocity and Sedimentation Equilibrium2008
- Size-Distribution Analysis of Macromolecules by Sedimentation Velocity Ultracentrifugation and Lamm Equation ModelingBiophysical Journal, 2000